India to Pakistan: Amikacin Export Trade Route

To import Amikacin formulations into Pakistan, the following approvals and registrations are mandatory:

• Drug Import License (D.I.L): Importers must obtain a D.I.L by submitting Form 2, accompanied by the applicable fee and an undertaking on Form 3. The D.I.L is issued on Form 5 and remains valid for two years from the date of issuance, unless suspended or canceled earlier. (dra.gov.pk)

• Product Registration: Each Amikacin formulation intended for import must be registered with DRAP. The registration process involves submitting a Common Technical Document (CTD) dossier, as specified in Form 5F. This dossier should include comprehensive data on the product's quality, safety, and efficacy. (dra.gov.pk)

• Import Clearance Certificate: For each shipment, importers are required to obtain an Import Clearance Certificate by applying through DRAP's online portal, providing mandatory documents. The processing timeline for this certificate is approximately five days. (dra.gov.pk)

• Good Manufacturing Practice (GMP) Compliance: Indian manufacturing facilities producing Amikacin formulations must comply with DRAP's GMP guidelines. While DRAP may conduct inspections of foreign manufacturing sites, it also recognizes GMP certifications from authorities in WHO-GMP reference markets. (dra.gov.pk)

Indian exporters of Amikacin formulations must adhere to the following quality and GMP standards to supply products to Pakistan:

• GMP Certification: Manufacturing facilities must hold valid GMP certifications that align with DRAP's standards. Compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP guidelines is recommended, as DRAP has been implementing these standards in a phased manner since 2019. (dra.gov.pk)

• Approved Facilities: While DRAP maintains a list of approved manufacturing facilities, specific details about Indian manufacturers currently approved to export Amikacin formulations to Pakistan are not publicly disclosed.

• Regulatory Actions: In April 2025, DRAP issued a recall alert for substandard pharmaceutical products, including Amikacin injections, due to quality concerns such as visible particulates. This underscores the importance of stringent quality control measures for exporters.

Several regulatory changes and initiatives have been introduced by DRAP between 2024 and 2026 that impact the importation of pharmaceutical products:

• Antimicrobial Data Submission: As of August 2025, registration holders of pharmaceutical products, including Amikacin formulations, are required to submit batch production and import data for antimicrobials regularly through the Drug Regulatory Information System (DRIS). This initiative aims to support antimicrobial stewardship policies to combat antimicrobial resistance (AMR) in Pakistan. (dra.gov.pk)

• Streamlined Registration Processes: In August 2025, DRAP announced the streamlining of the evaluation and processing of Form 5F (CTD) applications under S.R.O. 713(I)/2018. This policy aims to expedite the registration process for pharmaceutical products, potentially reducing approval timelines for importers. (dra.gov.pk)

• Implementation of PIC/S GMP Guidelines: DRAP has been implementing the PIC/S GMP guidelines in a staged manner since 2019. This ongoing initiative enhances the quality standards for pharmaceutical manufacturing, affecting both local producers and foreign exporters. (dra.gov.pk)

Importers and exporters must stay informed about these regulatory developments to ensure compliance and facilitate the smooth importation of Amikacin formulations into Pakistan.

Amikacin, an aminoglycoside antibiotic, is primarily used in Pakistan to treat severe bacterial infections, including those caused by multidrug-resistant strains. The demand for Amikacin formulations is driven by the prevalence of such infections, the country's healthcare infrastructure, and the availability of treatment options. In the fiscal year 2024-2025, Pakistan's healthcare expenditure increased by 8%, reflecting a growing investment in medical services and pharmaceuticals. While specific data on the market size for Amikacin formulations is limited, the importation of these products indicates a reliance on international suppliers to meet domestic demand. Domestic manufacturing of Amikacin formulations exists but is supplemented by imports to ensure adequate supply.

Pharmaceutical products classified under HS code 30049099, including Amikacin formulations, are subject to a 0% import duty in Pakistan. Additionally, these products are exempt from the General Sales Tax (GST), aligning with Pakistan's policy to facilitate the importation of essential medicines. There are no Free Trade Agreements (FTAs) between India and Pakistan that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is a significant supplier of Amikacin formulations to Pakistan, accounting for 12.6% of India's total exports of these products, valued at $2.7 million USD across 33 shipments. The primary exporter is Lincoln Pharmaceuticals Ltd, contributing $2.5 million USD to this trade. Other countries, including China and various European Union member states, also export Amikacin formulations to Pakistan, though specific data on their market shares is not readily available. India's competitive pricing and established pharmaceutical industry position it as a key player in supplying Amikacin formulations to the Pakistani market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 31.9% of the United States' imported finished dosage forms (FDFs) between 2020 and 2024. This dominance is supported by a robust manufacturing infrastructure, with 134 FDA-registered FDF facilities as of November 2024. The country's cost-effective production is attributed to economies of scale, competitive labor costs, and a well-established supply chain. Notably, Indian manufacturers such as Granules India Limited have received approvals from stringent regulatory bodies, including the U.S. FDA, for their facilities dedicated to finished dosage forms. This combination of scale, cost efficiency, and regulatory compliance positions India as a preferred source for Amikacin formulations.

When comparing Amikacin formulations from India, China, and the European Union (EU), several factors emerge:

• Price per Unit: Indian manufacturers offer competitive pricing due to lower production costs. In contrast, EU-produced formulations are typically more expensive, reflecting higher labor and operational expenses. Chinese products are cost-effective; however, concerns about quality and regulatory compliance can affect their market acceptance.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for adhering to international quality standards, with numerous facilities approved by the U.S. FDA and WHO-GMP. Chinese manufacturers have faced scrutiny over quality issues, leading to a perception of inconsistency. EU manufacturers are renowned for high-quality products but at a premium price point.

• Regulatory Acceptance in Pakistan: Pakistan's regulatory authorities recognize and accept Indian pharmaceutical products, facilitating smoother import processes. Chinese products may encounter additional scrutiny due to past quality concerns, while EU products are accepted but may be less cost-effective.

• Supply Reliability: Indian manufacturers have a proven track record of reliable supply chains, supported by extensive production capacities and established logistics networks. Chinese suppliers have experienced disruptions due to regulatory interventions and quality issues. EU suppliers offer reliability but with longer lead times and higher costs.

The India-Pakistan Amikacin formulation supply chain is characterized by:

• Manufacturing Capacity: India's pharmaceutical sector includes numerous facilities dedicated to the production of finished dosage forms, ensuring substantial capacity to meet demand. For instance, Granules India Limited operates multiple state-of-the-art plants for finished dosage forms.

• Packaging and Cold Chain Capabilities: Indian manufacturers have advanced packaging facilities and robust cold chain logistics, ensuring product integrity during transit.

• Regulatory Compliance: Indian pharmaceutical companies maintain high compliance with international regulatory standards, with many facilities holding approvals from the U.S. FDA, WHO-GMP, and other stringent authorities.

• Supply Disruptions: There have been no significant supply disruptions reported in recent years, indicating a stable supply chain.

• Capacity Constraints or Expansion Plans: Leading Indian manufacturers continue to invest in expanding their production capacities to meet growing global demand. For example, Granules India Limited received U.S. FDA approval for a new facility in Hyderabad in November 2025, enhancing their finished dosage manufacturing capabilities.

For Pakistani buyers sourcing Amikacin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and ensure timely transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet quality and regulatory standards.

• Regulatory Compliance: Verify that the selected suppliers have the necessary approvals from relevant authorities, such as the U.S. FDA and WHO-GMP, to ensure product quality and compliance.

By implementing these strategies, Pakistani buyers can secure a reliable and cost-effective supply of Amikacin formulations from India.

1. Verify Manufacturer's Registration with DRAP: Confirm that the Indian supplier is registered with the Drug Regulatory Authority of Pakistan (DRAP) for the specific Amikacin formulation intended for import.

2. Assess GMP Certification Validity: Obtain and review the supplier's Good Manufacturing Practice (GMP) certificate to ensure it is current and issued by a recognized regulatory authority.

3. Review Drug Master File (DMF): Request the supplier's DMF for Amikacin formulations to evaluate detailed information on manufacturing processes, controls, and quality standards.

4. Evaluate Quality Management Systems: Assess the supplier's quality management system to ensure it aligns with international standards and DRAP guidelines.

5. Confirm Regulatory Compliance: Ensure the supplier complies with all relevant regulations, including those set by DRAP and international bodies.

6. Conduct Risk Assessment: Perform a risk assessment of the supplier's operations, considering factors such as supply chain reliability, historical compliance, and financial stability.

7. Plan for On-Site Audit: Schedule an on-site audit of the supplier's manufacturing facility to verify compliance with GMP and other quality standards.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for regulatory and tariff purposes.

3. GMP Certificate: Issued by a competent authority, this certificate confirms the manufacturer complies with GMP standards.

4. Stability Data: Includes studies conducted under various conditions to demonstrate the product's shelf life and storage requirements, ensuring efficacy and safety over time.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing, processing, packaging, and storage of the drug product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organization (CDSCO), indicating the product is approved for sale in the manufacturer's country.

8. Insurance Certificates: Proof of liability insurance coverage, ensuring protection against potential claims related to product quality or safety.

1. Regulatory Actions: Recent warning letters or sanctions from regulatory bodies such as the U.S. FDA or WHO-GMP suspensions indicate compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability studies raises concerns about product shelf life and efficacy.

4. Limited Export History: Absence of a track record in exporting to regulated markets may indicate inexperience or non-compliance with international standards.

5. Resistance to Audits: Hesitation or refusal to allow facility inspections suggests potential compliance or quality issues.

1. Pre-Audit Desktop Review: Analyze all provided documentation, including quality manuals, SOPs, and previous audit reports, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Document findings and require the supplier to implement corrective and preventive actions within a specified timeframe.

4. Annual Re-Qualification: Conduct yearly audits to ensure ongoing compliance and address any new risks or changes in operations.

5. Remote Monitoring Options: Utilize virtual audits, regular reporting, and third-party inspections to maintain oversight between on-site visits.

By adhering to this structured approach, Pakistani pharmaceutical companies can effectively qualify Indian suppliers of Amikacin formulations, ensuring product quality, regulatory compliance, and patient safety.